Man Group plc Takes Position in Vanda Pharmaceuticals Inc. $VNDA

Man Group plc bought a new position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 153,557 shares of the biopharmaceutical company’s stock, valued at approximately $940,000.

Several other large investors also recently modified their holdings of the business. BlackRock Inc. purchased a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $46,841,000. AIGH Capital Management LLC bought a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter worth approximately $12,510,000. Millennium Management LLC grew its position in shares of Vanda Pharmaceuticals by 220.0% in the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock worth $9,821,000 after buying an additional 1,470,898 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of Vanda Pharmaceuticals by 552.3% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 708,428 shares of the biopharmaceutical company’s stock valued at $6,248,000 after buying an additional 599,818 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of Vanda Pharmaceuticals by 945.9% during the second quarter. Marshall Wace LLP now owns 471,720 shares of the biopharmaceutical company’s stock valued at $2,227,000 after buying an additional 426,620 shares during the period. 88.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. B. Riley Financial restated a “buy” rating and issued a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Wall Street Zen cut shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Finally, HC Wainwright cut their target price on shares of Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Vanda Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $13.70.

Vanda Pharmaceuticals Price Performance

VNDA opened at $5.34 on Friday. The company has a current ratio of 1.61, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. The company has a market cap of $322.86 million, a price-to-earnings ratio of -1.15 and a beta of 0.64. The stock has a fifty day simple moving average of $5.52 and a two-hundred day simple moving average of $6.45. Vanda Pharmaceuticals Inc. has a 12-month low of $4.27 and a 12-month high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). The business had revenue of $50.53 million for the quarter, compared to the consensus estimate of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. Research analysts predict that Vanda Pharmaceuticals Inc. will post -3 earnings per share for the current fiscal year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.